title: Intravenous immunoglobulin for myasthenia gravis.
abstract: BACKGROUND
  Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007.
  
  
  OBJECTIVE
  To examine the efficacy of IVIg for treating exacerbations of myasthenia gravis or for chronic myasthenia gravis.
  
  
  METHODS
  We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 October 2011), CENTRAL (2011, Issue 3), MEDLINE (January 1966 to September 2011) and EMBASE (January 1980 to September 2011) using 'myasthenia gravis' and 'intravenous immunoglobulin' as the search terms.
  
  
  METHODS
  All randomised controlled trials (RCTs) or quasi-RCTs in which IVIg was compared with no treatment, placebo or plasma exchange, in people with myasthenia gravis.
  
  
  METHODS
  One review author extracted the data and two others checked these data. For methodological reasons, no formal meta-analysis was performed.
  
  
  RESULTS
  We identified seven RCTs. These trials differ in inclusion criteria, comparison with alternative treatment and outcomes. In a trial comparing IVIg with placebo, including 51 participants with myasthenia gravis worsening, the mean difference (MD) in quantitative myasthenia gravis score (QMGS) (MD 95% CI) after 14 days was: -1.60 (95% CI - 3.23 to 0.03) this result being borderline statistically significant in favour of IVIg. In an unblinded study of 87 participants with exacerbation comparing IVIg and plasma exchange there was no difference in myasthenic muscle score (MMS) after 15 days (MD -1.00; 95% CI -7.72 to 5.72). In a study of 84 participants with worsening myasthenia gravis there was no difference in change in QMGS 14 days after IVIg or plasma exchange (MD -1.50; 95% CI -3.43 to 0.43). In a study of 12 participants with moderate or severe myasthenia gravis, which was at high risk of bias from skewed allocation, the mean fall in QMGS both for IVIg and plasma exchange after four weeks was significant (P < 0.05). A study with 15 participants with mild or moderate myasthenia gravis found no difference in change in QMGS 42 days after IVIg or placebo (MD 1.60; 95% CI -1.92 to 5.12). A study included 33 participants with moderate exacerbations of myasthenia gravis and showed no difference in change in QMGS 14 days after IVIg or methylprednisolone (MD -0.42; 95% CI -1.20 to 0.36). All these three smaller studies were underpowered. The last trial, including 168 people with exacerbations, showed no evidence of superiority of IVIg 2 g/kg over IVIg 1 g/kg on the change of MMS after 15 days (MD 3.84; 95% CI -0.98 to 8.66). Adverse events due to IVIg were moderate (fever, nausea, headache), self-limiting and subjectively less severe than with plasma exchange (although, given the available data, no statistical comparison was possible). Other than where specific limitations are mentioned the trials were generally at low risk of bias.
  
  
  CONCLUSIONS
  In exacerbation of myasthenia gravis, one RCT of IVIg versus placebo showed some evidence of the efficacy of IVIg and two did not show a significant difference between IVIg and plasma exchange. Another showed no significant difference in efficacy between 1 g/kg and 2 g/kg of IVIg. A further, but underpowered, trial showed no significant difference between IVIg and oral methylprednisolone. In chronic myasthenia gravis, there is insufficient evidence from RCTs to determine whether IVIg is efficacious.
authors.affiliation: Service de Réanimation, Hopital Raymond Poincaré (APHP), 92380 Garches, France. mp.gajdos@9online.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Gajdos
authors.forename: Sylvie
authors.initials: S
authors.lastname: Chevret
authors.forename: Klaus V
authors.initials: KV
authors.lastname: Toyka
mesh_terms: D002908:Chronic Disease; D018450:Disease Progression; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000628:therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010951:Plasma Exchange; D016032:Randomized Controlled Trials as Topic
chemical_list: D016756:Immunoglobulins, Intravenous; D018696:Neuroprotective Agents; D008775:Methylprednisolone